You are on page 1of 13

JOURNAL READING

MANAGEMENT OF TINEA CORPORIS, TINEA CRURIS, AND TINEA PEDIS : A


COMPERHENSIVE REVIEW
A l o k Ku m a r S a h o o, Ra h u l M a h a j a n

OLEH :
Betharlitha Maharlika
2012730018

PEMBIMBING:
Dr. Bowo Wahyudi, Sp.KK

KEPANITERAAN KLINIK ILMU PENYAKIT KULIT DAN KELAMIN


FAKULTAS KEDOKTERAN UNIVERSITAS MUHAMMADIYAH JAKARTA
RUMAH SAKIT UMUM DAERAH KOTA BANJAR
PERIODE PERIODE 23 OKTOBER 26 NOVEMBER 2017
INTRODUCTION

The prevalence of superficial mycotic


infection worldwide is 2025% Dermatophytes
Tinea Capitis

Tinea Faciei

Tinea Barbe

Trichophyton
Tinea Manus
Dermatophyte Genera Epidermophyton Affected Site
Tinea Cruris
Microsporum

Tinea Pedis

Tinea Unguium

Tinea Corporis
AIM

To revisit this important topic and recent advances in the pathophysiology and management of
tinea corporis, tinea cruris, and tinea pedis
PATHOGENESIS OF DERMATOPHYTOSIS

Genetics Immunology

Innate immune Adaptive immune


Host Agent
response response

environment Nonspecific
response
DIAGNOSIS OF DERMATOPHYTOSIS
Microdilution
Laboratory investigations
method

Direct Culture and


microscopic antifungal
examination sensitivity Minimum fungicidal
concentration (MFC)
Dermatophyte determination
identification
DIAGNOSIS OF DERMATOPHYTOSIS

Histopathology
Mass spectrometry

Dermoscopy

Reflectance confocal microscopy


Polymerase chain reaction
TREATMENT OF CUTANEOUS DERMATOPHYTOSIS

Nonpharmacologic Pharmacologic

Topical Systemic
PENDAHULUAN
PENDAHULUAN
PENDAHULUAN
PENDAHULUAN
SYSTEMIC MEDICATION
SPECIAL SITUATIONS

Majocchis Tinea imbricate Immunosuppressed Chronic


granuloma and and pregnancy dermatophytosis
pseudoimbricata
CONCLUSIONS
Topical terbinafine for 4 weeks appears to be the treatment of choice for limited
disease.

Terbinafine (250500 mg/day for 26 weeks) and itraconazole (100200 mg/day


for 24 weeks)
THANK YOU!

You might also like